Simone Di Cola
Overview
Explore the profile of Simone Di Cola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan S, Sansoni S, Di Cola S, Lapenna L, Merli M
Nutrients
. 2025 Feb;
17(3).
PMID: 39940438
Liver cirrhosis is associated with significant nutritional challenges, including malnutrition, sarcopenia, and frailty, which impact clinical outcomes. The severity of these issues may vary between inpatient and outpatient settings, but...
2.
Barberi L, Porcu C, Boccia C, Cosentino M, Nicoletti C, Peruzzi B, et al.
J Cachexia Sarcopenia Muscle
. 2025 Feb;
16(1):e13675.
PMID: 39921321
Background: The mechanisms underlying muscle alteration associated to alcoholic liver disease (ALD) are not fully understood and the physiopathologic mediators of the liver-muscle interplay remains elusive. We investigated the role...
3.
Lapenna L, Di Cola S, Merli M
Metab Brain Dis
. 2024 Nov;
40(1):29.
PMID: 39570425
Hepatic encephalopathy (HE) is a common condition in patients with cirrhosis, representing the second most frequent cause of decompensation. Approximately 30-40% of patients with cirrhosis will experience overt HE during...
4.
Di Cola S, DAmico G, Merli M
J Hepatol
. 2024 Jul;
81(4):e194-e195.
PMID: 39002640
No abstract available.
5.
Cicala M, Gori M, Balestrieri P, Altomare A, Tullio A, Di Cola S, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892004
Vedolizumab (VDZ) is used for treating inflammatory bowel disease (IBD) patients. A study investigating colonic epithelial barrier function ex vivo following VDZ is lacking. This work aims to evaluate ex...
6.
Di Cola S, DAmico G, Caraceni P, Schepis F, Loredana S, Lampertico P, et al.
J Hepatol
. 2024 May;
81(4):641-650.
PMID: 38782120
Background & Aims: Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over...
7.
Di Cola S, Khan S, Lapenna L, Merli M
Expert Opin Emerg Drugs
. 2024 Mar;
29(2):81-91.
PMID: 38549232
Introduction: Malnutrition and sarcopenia are common and impact the prognosis in patients with liver cirrhosis. The etiology is multifactorial and includes periods of reduced caloric intake, increased catabolism and direct...
8.
Di Cola S, Lapenna L, Gazda J, Fonte S, Cusi G, Esposito S, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38276106
Liver transplantation is currently the only curative therapy for patients with liver cirrhosis. Not all patients in the natural course of the disease will undergo transplantation, but the majority of...
9.
Mehta G, Riva A, Ballester M, Uson E, Pujadas M, Carvalho-Gomes A, et al.
Hepatol Commun
. 2023 Oct;
7(11).
PMID: 37870985
Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are...
10.
Lapenna L, Di Cola S, Gazda J, de Felice I, Gioia S, Merli M
J Clin Exp Hepatol
. 2023 Sep;
13(5):794-803.
PMID: 37693277
Since 1988, transjugular intrahepatic portosystemic shunt (TIPS) has been an effective therapy for portal hypertension in many settings. Thanks to continuous technical improvements and a wiser selection of patients, excellent...